| Intermune Drops Right Back Down Again Derek Lowe submits: Back in March, Intermune's stock saw a sudden jump on news that an FDA advisory committee treated their drug pirfenidone more positively than expected. But the agency is in no way committed to following these recommendations, and yesterday they turned down the drug, sending Intermune stock right back down into the basement again. Pirfenidone was, even after the advisory committee, an iffy proposition. It made it through one Phase III trial, but missed its endpoints on another. And even though there's no current treatment for idiopathic pulmonary fibrosis, there's no use in telling people that there is one (and asking their insurance companies to pay for it) if there really isn't. The company isn't saying much, but all indications are the the FDA is concerned about efficacy: they aren't convinced that the drug really works, and will want fresh clinical trial data before reconsidering approval.Complete Story » seekingalpha.com |
High-Risk Insurance Pools Launched As new high-risk insurance pools begin taking applications Thursday, U.S. officials say they may shift funding among states if the money runs out more quickly in some states than others. online.wsj.com |
Insight Imaging Completes Acquisition of Eight Imaging Centers (Business Wire) LAKE FOREST, Calif.----InSight Health Services Holdings Corp. today announced that it had completed the previously announced acquisition of eight imaging centers in the Phoenix, Arizona, El Paso, Texas, and Las Cruces, New Mexico areas from subsidiaries of MedQuest, Inc. and Novant Health, Inc. us.rd.yahoo.com |
Fall Back Into Health & Fitness - VIDEO Nationally recognized fitness, nutrition and lifestyle expert Kelli Calabrese provides the latest trends in fitness and nutrition. feedproxy.google.com |
Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes [PR Newswire] - Spherix Incorporated , an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 3 study of D-tagatose as a monotherapy in Type 2 diabetes showed a statistically significant reduction in HbA1c levels of 0.4% at 10 months in relatively healthy people with diabetes *. Â The reduction was even more pronounced among PP patients treated in the U.S., and the reduction in HbA1c generally increased over the 10 months patients were treated . us.rd.yahoo.com |